Background
Results
For most cancers, the monthly inpatient costs per patient remain stable or increased gradually from 12 months to 3 months prior to death and then increased steeply from 2 months prior to death. The mean monthly inpatient costs per patient were highest for acute myeloid leukemia (AML) throughout the last year of life; all solid tumors had similar trends of monthly inpatient costs. The mean monthly inpatient costs for AML increased from $5,465 (SD, $5,248) in 12 months prior to death to $15,033 (SD, $11,864) in the last month. The monthly outpatient costs per patient showed similar, gradually decreasing trends for most cancers. The mean outpatient costs were highest for kidney cancer; the costs sharply decreased from $954 (SD, $1,346) in 12 months prior to death to $424 (SD, $736) in the last month. The proportion of inpatients receiving chemotherapy in the last month of life was highest for AML (77%), followed by liver cancer (67%) and breast cancer (56%).
Conclusion
The monthly inpatient medical care costs per patient with cancer increased as the patient approached death, while the monthly outpatient costs decreased. A considerable proportion PLOS ONE | https://doi.org/10.1371/journal.pone.0197891 June 7, 2018 1 / 13 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Introduction

Materials and methods
Database
We used the Health Insurance Review and Assessment Service (HIRA) database, which contains national health insurance claims data in Korea. The HIRA database includes cost information on all medical services and prescription drugs that are reimbursed by the health insurance authority. We identified the patients who had been treated for the primary diagnoses of one of the 13 most prevalent cancers in Korea and died between January 1, 2013 and December 31, 2015 by linking HIRA claims data with the mortality dates derived from the Statistic Korea. Personal identification numbers in the HIRA database were anonymized before providing to researchers. Diagnoses were coded according to the International Classification of Disease-10 th revision (ICD-10). The 13 cancers were stomach cancer (ICD-10 code, C16), liver cancer (C22), lung cancer (C34), breast cancer (C50), colorectal cancer (C18, C19, C20), kidney cancer (C64, C65), prostate cancer (C61), acute myeloid leukemia (AML; C920, C925, C926, C927, C928, C929, C930, C942), non-Hodgkin's lymphoma (C85), cervical cancer (C53), ovarian cancer (C56), pancreatic cancer (C25), and thyroid cancer (C73).
Monthly medical care costs per patient
We extracted claims data for the identified decedents for 360 days before death. We calculated the mean number of inpatient and outpatient days as well as the monthly medical care costs per patient by cancer site and patient setting (inpatient vs. outpatient). Monthly costs were calculated on the basis of 30 days per month by equally dividing 360 days into 12 months. Outpatient costs were determined by summing claimed amounts on all services provided for the decedents in the outpatient setting each month. Inpatient costs were assumed to be equally spread over the duration of hospitalization. In other words, total costs incurred during a period of hospitalization that lasted more than a day were divided by the number of inpatient days based on the assumption that costs per inpatient day were the same throughout the period. The resulting inpatient costs per day were multiplied by the number of inpatient days in a given month to produce the monthly inpatient costs. For example, if a patient was hospitalized on day 28 of month 11 and then discharged on day 2 of month 12, we counted 2 days in month 11 and 2 days in month 12. Costs in Korean won were converted to US$ using the conversion rate of 1,100 won/US$.
Monthly costs of drug therapy and chemotherapy per patient
We calculated drug therapy costs as a proportion of total medical care costs, the proportion of patients receiving chemotherapy, and the ratio of mean drug therapy costs to mean chemotherapy costs in the last month of life by cancer site and patient setting. We also calculated the monthly costs of drug therapy and chemotherapy per patient in the last year of life. The mean drug therapy costs were defined as the mean of drug therapy costs per patient in all patients who were treated with prescription drugs each month. Only a portion of all cancer patients who were on drug therapy received chemotherapy. The mean chemotherapy costs were defined as the mean of chemotherapy costs per patient in all patients who were treated with chemotherapy each month. As a result, the mean chemotherapy costs per patient may be greater than the mean drug therapy costs per patient. The mean and standard deviation (SD) were calculated for all continuous variables. All analyses were performed by using SAS-EG version 4.3 (Cary, NC, USA). The approval of the Institutional Review Board for this study with the general population was waived under Article 16 of the Rule of the Bioethics and Safety Act in Korea [19] .
Results
We included a total of 134,633 males and 75,039 females in the analysis ( Table 1 ). The most common cancer was lung cancer for males (n = 39,142) and colorectal cancer for females (n = 13,883). The mean age ranged from 61 to 77 years for males and from 58 to 72 years for females depending on cancer site. For all cancers, the mean number of inpatient days per patient increased as the patient approached death; the number of inpatient days nearly doubled in the last month as compared to 12 months prior to death ( Table 2 ). In contrast, the number of outpatient days remained stable.
For most cancers, the monthly inpatient costs per patient remain stable or increased gradually from 12 months to 3 months prior to death and then increased steeply from 2 months prior to death (Table 3, S1 Table) . The mean monthly inpatient costs per patient were highest for AML throughout the last year of life; all solid tumors had similar trends of monthly 17  17  18  18  20  3  3  3  3  3  3  3  3  3  3  3  3   Liver  8  9  10  10  10  10  11  11  12  13  15  18  2  2  2  2  2  3  3  3  3  3  3  2   Stomach  9  11  11  11  11  11  12  12  13  14  16  20  2  2  2  2  2  2  2  3  3  3  3  2   Breast  9  11  12  12  12  12  13  13  14  15  16  19  3  3  3  3  3  3  3  3  3  3  3  3   Prostate  11  15  16  15  16  16  16  17  16  17  17  18  2  2  2  2  2  2  2  2  2  2  2  2   Non  -Hodgkin's lymphoma   9  12  12  12  13  14  14  14  15  16  16  18  3  2  2  2  2  2  3  3  3  2  2  2   Thyroid  10  16  16  16  16  18  17  18  17  17  18  19  2  2  2  2  2  2  2  2  2  2  2  2   Cervical  9  11  12  12  13  13  13  14  15  16  18  21  4  4  4  4  4  4  4  3  3  3  3  2   Pancreatic  9  11  11  11  11  11  11  12  13  14  16  20  4  3  3  3  3  3  3  3  3  3  3  3   Ovarian  9  11  11  11  12  12  12  13  14  15  18  21  3  3  3  3  3  3  3  3  3  3  3  3   Lung  8  10  10  11  11  11  11  12  13  14  16  19  3  3  3  3  3  3  3  3  3  3  3  2   Colorectal  9  12  12  12  13  13  14  14  15  16  18  20  3  3  3  3  3  3  3  3  3  3  3  2   Kidney  9  12  12  12  12  13  14  14  14  15  16  19  2  2  2  3  3  3  3  3  3  3  3  2 https://doi.org/10.1371/journal.pone.0197891.t002 inpatient costs. The mean monthly inpatient costs for AML increased from $5,465 (SD, $5,248) in 12 months prior to death to $15,033 (SD, $11,864) in the last month. In contrast, the mean monthly outpatient costs showed similar, gradually downward trends for most cancers. The mean outpatient costs were highest for kidney cancer; the costs sharply decreased from $954 (SD, $1,346) in 12 months prior to death to $424 (SD, $736) in the last month. The mean outpatient costs for most of the other solid tumors remained stable and then slightly decreased as the patients approached death. Among the patients who incurred inpatient costs in the last month of life, approximately 20% of the inpatient medical costs were spent on drug therapy for most cancers; however, the proportion was 30% for AML (Table 4 ). The proportion of inpatients receiving chemotherapy in the last month was highest for AML (77%), followed by liver cancer (67%) and breast cancer (56%). The ratio of the mean chemotherapy cost to mean drug therapy cost was highest for prostate cancer and non-Hodgkin's lymphoma (both 23%), followed by kidney cancer (22%). In the outpatient setting, over 30% of total medical care costs in the last month were spent on drug therapy for most cancers; the percentage was highest for kidney cancer (87%), followed Costs in Korean won were converted to US$ using the conversion rate of 1,100 won/US$.
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by prostate cancer (71%) and pancreatic cancer (64%). The proportion of outpatients receiving chemotherapy was highest for prostate cancer (33%), followed by AML (29%), lung cancer and pancreatic cancers (28%), and kidney cancer (27%); the proportion was lowest for thyroid cancer (7%). The ratio of the mean chemotherapy costs to the mean drug therapy costs in the outpatient setting was highest for thyroid cancer (1.98), followed by kidney cancer (1.96). For inpatients, the mean drug therapy costs increased but the mean chemotherapy costs decreased as the patient approached death (Fig 1C, Fig 1D, Fig 1E, S2 Table, S3 Table) . For example, the mean inpatient drug therapy costs for AML more than doubled from $1,809 (SD, $2,204) in 12 months before death to $4,572 (SD, $4,923) in the last month; yet the mean chemotherapy costs decreased from $649 (SD, $890) to $530 (SD, $928) during the same period. The mean inpatient chemotherapy costs were consistently low for liver ($93 in 12 months before death to $77 in the last month) and thyroid cancers ($121 to $70, respectively); these costs were high initially but declined near the end of life for most of the other solid tumors. The mean inpatient drug therapy costs were markedly higher for AML than for other cancers. Among outpatients, the mean drug therapy and chemotherapy costs were high for kidney cancer in 12 months before death but dramatically declined near the end of life (from $929 to $369 for drug therapy and from $1,880 to $722 for chemotherapy, respectively); however, these costs remained stable for all other cancers throughout the year and declined slightly near death (Fig 2C, Fig 2D, Fig 2E, S2 Table, S3 Table) .
Discussion
This population-based study examined the monthly costs of EOL care per patient including drug therapy and chemotherapy for inpatient vs. outpatient care in the last year of life among decedents from one of the 13 most prevalent cancers in Korea based on national health insurance claims data. We showed that the monthly inpatient costs per patient increased as the patient approached death for all cancers while the monthly outpatient costs per patient decreased during the same period. Similarly, in the United States, inpatient costs per cancer decedent increased from $1,785 in 6 months before death to $20,559 in the last month, while outpatient costs decreased from $6,021 to $2,238, respectively [20] . Our data showed that the mean inpatient costs per patient increased steeply in the last few months of life for most cancers while the number of inpatients simultaneously increased. In addition, a substantial proportion of patients received chemotherapy in the inpatient setting in the last month of life, suggesting that a high proportion of EOL care costs incurred for inpatient care. This is consistent with the finding of another study in Korea; approximately 80% of spending per cancer decedent in Korea were associated with inpatient care [13] . These findings suggest that most cancer deaths in Korea occur in hospitals and that there are opportunities to reduce the costs and improve the quality of cancer care by providing greater access to hospice care at the end of life. In comparison, inpatient costs were responsible for 55% of total cancerrelated costs in the last six months of life among the commercially insured U.S. patients; remaining 41% and 4% were for outpatient services and hospice costs, respectively [20] .
While the proportion of outpatients receiving chemotherapy in the last month of life tended to be low, the ratio of the mean chemotherapy costs to the mean drug therapy costs was considerably high in these patients. This is probably because chemotherapy costs comprise most of drug therapy costs and not many other costs are incurred in the outpatient setting. On the contrary, the proportion of inpatients receiving chemotherapy tended to be high, but the ratio of the mean chemotherapy costs to the mean drug therapy costs was low among these patients. This is probably due to higher costs of non-pharmacological treatments used in the inpatient setting. These findings suggest the aggressiveness of cancer treatments even in the last months of life. Another study in Korea also documented a substantial proportion of cancer decedents receiving aggressive medical care near the end of life; 50.3% and 5.7% received chemotherapy in the last 2 months and 2 weeks of life, respectively [16] . Similarly, U.S. studies reported that older patients with cancer receive more aggressive EOL care including chemotherapy in a few weeks prior to death and that chemotherapy for patients with advanced cancer was associated with higher costs of EOL care [17, 18] .
We showed that the mean inpatient medical care costs of cancer per patient in the last year of life in Korea varied by cancer site with AML incurring the highest costs, which is consistent with the findings of a 2005 study [21] . We further showed that the inpatient costs for AML were more than twice the costs for other cancers and that the differences diverged even more in the last two months of life. As AML is a cancer that progresses fast, patients with AML often die while receiving chemotherapy. For that reason, the proportion of inpatients receiving chemotherapy in the last month of life may have been high (77%). The mean inpatient medical costs and drug therapy costs are markedly higher for AML than for other cancers; in contrast, the mean inpatient chemotherapy costs are comparable between AML and other cancers. This suggests that the costs of drug therapy other than chemotherapy per patient are substantial for AML; the costs may be attributable to blood transfusion, which is critical for the treatment of AML [22] .
We showed that the mean outpatient chemotherapy costs for kidney cancer were very high initially and then gradually declined until the rate of decrease becomes steeper in the 3 months before death. It is plausible that recently introduced, orally administered, pricy targeted drugs might have been used for patients with kidney cancer in the last year of life until these therapies were discontinued when the patients approach the end of life [23, 24] . Although only 27% of outpatients with kidney cancer received chemotherapy in the last month of life, the mean chemotherapy costs per patient were very high among these patients. Furthermore, the mean chemotherapy costs among outpatients with kidney cancer receiving chemotherapy in the last month of life were 1.96 times the mean drug therapy costs among outpatients receiving drug therapy, suggesting that highly expensive chemotherapy were used for patients with kidney cancer even in the last month of life.
The ratio of the mean chemotherapy costs to the mean drug therapy costs in the last month was highest for outpatients with thyroid cancer (1.98). This is probably because no other drugs than pricy chemotherapy were used to treat these patients [25] . Our findings suggest that only a small proportion (7%) of outpatients with thyroid cancer received pricy targeted chemotherapy in the last month of life. If this is the case, the mean drug therapy costs can be low among patients not receiving chemotherapy but the mean costs of targeted drug therapy can be high among the patients on chemotherapy.
Using national health insurance data, this study provides recent evidence on extraordinarily high costs of EOL cancer care in the inpatient setting that continue to increase until the last month of life. This analysis of population-based data presents system-wide costs of cancer care without a bias that can occur in an analysis of data from a limited number of patients or medical care institutions. Moreover, this is the first study to examine monthly cost trajectories for drug therapy and chemotherapy by cancer site and patient setting among end-stage cancer patients in Korea. We showed that the mean monthly inpatient care costs per cancer patient increased steeply very close to death for most cancers and that chemotherapy was used for a substantial proportion of patients even in the last month of life. These findings suggest the likelihood of unnecessary medical spending for terminal cancer care and highlight the importance of optimizing EOL care for cancer patients. Furthermore, our findings present policy implications for cancer care in Korea where hospice and home care services are not commonly used to care for terminal cancer patients [26] . While home care and hospice care services appropriate for terminal cancer patients are not widely available in Korea, the fee-for-service payment system in Korea provides an incentive for excessive medical care services. To control the unnecessarily aggressive and excessive treatment of cancer patients nearing death and resulting cost increases, policy interventions are needed, which could include a payment system reform (i.e., transition into capitation or value-based care) and promotion of health care providers' communication with patients. In the U.S., having EOL discussions with the oncologist was suggested as a way to reduce medical care utilization and costs and to increase the quality of life of the patient [27] ; the mean medical care costs in the last week of life were 35.7% lower among the patients who had EOL discussions, compared with $2,917 for those who did not [28] .
Although this analysis of real world data provides a basis for developing evidence-based policy interventions for cancer care, this study has the following limitations. First, the HIRA database used in this study includes only medical care services that are reimbursed by the national health insurance system. Thus, non-reimbursable services such as caretaker services that were paid for by the patients out of pocket were not included in the analysis. Future studies should include costs of these services to estimate the entire economic burden of cancer care. Second, while being hospitalized for cancer, patients can receive inpatient care for unrelated conditions, suggesting the possibility of overestimation of cancer care costs. Conversely, if patients were primarily hospitalized for conditions other than cancer, cancer treatment costs may have been excluded from the analysis, thus underestimating cancer care costs. Third, our findings are descriptive only and do not account for differences in patient demographics or clinical profiles. The objective of this study was to describe cancer care costs in all cancer decedents in the last year of life by cancer site but not to investigate factors influencing the costs. The claim data used in our analysis were collected for the primary purpose of reimbursement. As a result, aside from patient sociodemographic information, the data include limited clinical information. An investigation of factors influencing cancer care costs would best be conducted by using claims data merged with an external data source with rich clinical information, such as electronic medical records, which should be left for future research.
Conclusion
In conclusion, medical care costs for cancer in the last year of life showed different trends depending on patient setting. The mean monthly inpatient medical care costs per patient increased and the mean monthly outpatient costs per patient decreased for all cancers as the patient approached death. The mean monthly inpatient medical care costs were highest for AML and increased steeply in parallel with drug therapy over the last year of life. The mean monthly outpatient medical care, drug therapy, and chemotherapy costs were highest for kidney cancer and decreased sharply over the last year of life. A considerable proportion of patients received chemotherapy in the inpatient setting in the last month of life. Our findings highlight the need to examine the appropriateness of aggressive treatments including chemotherapy among patients with terminal cancer to reduce the undue financial burden on the patient, the family, and the insurance system. 
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